Certain spinal fluid biomarkers may predict responses to NurOwn
Treatment with NurOwn (debamestrocel), which BrainStorm Cell Therapeutics is developing for amyotrophic lateral sclerosis (ALS), may bring about changes in…
Articles by Margarida Maia, PhD
ALS Society-Brain Canada grant aids work into protein clumping in ALS
Researchers at the University of Waterloo will use a CA$125,000 (about $93,000) grant from the ALS Society of Canada…
Dewpoint wins grant to develop its condensate-modifying therapies
Dewpoint Therapeutics has received a grant from the Target ALS Foundation to advance the development of small molecules…
Edaravone formulation FAB122 fails to slow ALS progression
Note: This story was updated Jan 24, 2024, to correct that Radicava and Radicava Oral Suspension are available in Switzerland…
Stem cell-based therapy deemed safe in Phase 2 study
CL2020, a stem cell-based therapy that was being developed by the Life Science Institute, part of Mitsubishi Chemical, was…
Five toxic chemicals in air may raise, by 3 to 6 times, risk of ALS
Exposure to certain toxic airborne chemicals used in industry significantly increases — by up to six times — the odds…
Transcranial stimulation seen to boost muscle strength, life quality
Transcranial stimulation — a noninvasive technique that delivers low electrical currents to the brain to fine-tune nerve cell activity —…
BrainStorm, FDA map out next steps for Phase 3b testing of NurOwn
BrainStorm Cell Therapeutics has had a meeting with the U.S. Food and Drug Administration (FDA) seeking an agreement on…
Coya, Dr. Reddy’s collaborate to advance COYA 302 for ALS
Under a new agreement, Coya Therapeutics’ amyotrophic lateral sclerosis (ALS) treatment candidate COYA 302 — which aims to suppress…
PrimeC safe, shows trends toward slowing ALS progression: Trial data
NeuroSense Therapeutics’ PrimeC was found to be safe and well tolerated in a Phase 2b trial, and use of the…